High-Intensity Focused Ultrasound Ablation in Treating Patients With Progressive Prostate Cancer
NCT ID: NCT00987675
Last Updated: 2013-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
26 participants
INTERVENTIONAL
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase II trial is studying the side effects of high-intensity focused ultrasound ablation and to see how well it works in treating patients with progressive prostate cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To evaluate the side effects and patient-reported quality of life outcomes of the index (largest) lesion treatment with high-intensity focused ultrasound ablation in patients with progressive ≤ T3b, N0, M0 prostate cancer.
Secondary
* To determine the success of this treatment by demonstrating the absence of cancer in the treated or ablated area on the 6 month post-treatment transrectal ultrasound biopsy.
* To evaluate the prostate-specific antigen (PSA) kinetics after index lesion ablation treatment in these patients.
* To evaluate the proportion of these patients who, after undergoing index lesion control treatment, require androgen blockade at the 12-month follow-up.
OUTLINE: Patients undergo transrectal high-intensity focused ultrasound ablation (HIFU) to the index lesion and other identifiable secondary lesions. Patients are evaluated at 6 months and may repeat HIFU treatment.
Patients undergo MRI and ultrasound at baseline and periodically thereafter, and blood samples are collected periodically for PSA, renal function, full blood count, and testosterone levels. Patients also complete questionnaires (IPSS, IPSS-QOL, ICS, FACT-P, and IIEF-5) at baseline; at 6 weeks; and at 3, 6, 9 and 12 months.
After completion of study treatment, patients are followed at 2 and 6 weeks and at 3, 6, 9, and 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pharmacological study
questionnaire administration
assessment of therapy complications
high-intensity focused ultrasound ablation
quality-of-life assessment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed prostate cancer on transrectal ultrasound or transperineal template prostate biopsies meeting the following criteria:
* Stage ≤ T3b, N0, M0 disease
* Gleason score ≤ 8
* Serum PSA ≤ 20 ng/mL
* No metastatic disease and nodal spread by staging CT or MRI
* Negative bone scan within the past 6 months
* Index lesion or other secondary lesions with a volume of ≥ 0.5 cc by MRI
* Secondary lesions are included in the treatment provided ≥ 1 neurovascular bundle and 40-50% of prostatic tissue can be preserved
PATIENT CHARACTERISTICS:
* Able to tolerate a transrectal ultrasound
* Able to undergo major surgery as assessed by a consultant anesthesiologist
* Able to undergo MRI scanning (i.e., no severe claustrophobia, permanent cardiac pacemaker, metallic implant)
* No urethral stricture or presence of metal implants or stents in the urethra
* No prostatic calcification or cysts (on transrectal ultrasound) that would interfere with effective delivery of HIFU therapy
* No allergy to latex
PRIOR CONCURRENT THERAPY:
* No prior radiotherapy
* No prior treatment with any of the following:
* Transurethral resection of the prostate or equivalent procedures within the past 2 years
* High-intensity focused ultrasound ablation (HIFU)
* Cryosurgery
* Thermal or microwave therapy to the prostate
* No prior significant rectal surgery that prevents insertion of the transrectal HIFU probe
* More than 12 months since prior androgen suppression or hormone treatment for prostate cancer
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College London Hospitals
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hashim Uddinn Ahmed, MD
Role:
University College London Hospitals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University College Hospital
London, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hashim Uddinn Ahmed, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCLH-09-H0714-7
Identifier Type: -
Identifier Source: secondary_id
CDR0000650138
Identifier Type: -
Identifier Source: org_study_id